Odylia Therapeutics is a nonprofit biotech working to accelerate the development of treatments for people with rare diseases.

At Odylia, we accelerate therapeutic development for people with rare diseases, changing the way treatments are brought from the lab to the clinic. We strive to bring life altering treatments to people with genetic disease regardless of prevalence or commercial interest. 
Odylia is shifting the paradigm to focus on proven science and removing traditional roadblocks. We work to lower costs, reduce development time, focus research, and continuously drive successful programs towards clinical trials and regulatory approval. Strategic collaborations with patient groups, research labs, and commercial partners facilitate our work to ensure treatments are safe, effective, and ultimately reach patients who need them.

Odylia challenges the traditional approach to drug development through:

1. Lower cost of development
Lower licensing fees to decrease development costs and ensure continued commitment to program success

2. Increase speed of development
Challenge traditional approaches through regulatory engagement

Streamline development through strategic partnerships and a platform approach to drug development

3. Enable the entire ecosystem
Provide expertise through in-house Brydge Solutions and leveraging the Odylia Board

Enable the entire ecosystem through Initiatives that impact the broader field

Odylia Therapeutics

1258415673

1435915265

1737023302

We are a nonprofit, so instead of charging fees we rely on the generosity of donors like you.

Choose a donation for Every.org

2074652487

2516130445

2883383521

339774024

3605944885

3755280456

3794356679

3868271524

410756082

4291266865

761293274

772217036

2729980760

3440869557

671754822

1014384873

1112422858

2028390811

220342792

2266630408

2456389719

2519810400

2539558839

2826465835

2843798242

2898624300

2916352438

3259439560

3642494300

3902459442

4136002033

4177183036

4250940449

585491400

641510716

91682487